Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $485 from $425 and keeps an Underweight rating on the shares following the earnings report. The firm says it was “overly bearish” on Medpace’s demand environment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace Holdings Reports Strong Q3 2025 Results
- Medpace Holdings Inc. Reports Strong Q3 2025 Growth
- Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning
- Closing Bell Movers: Tesla and IBM fall as Q3 results disappoint
- Medpace Holdings: Strong Q3 Performance Amid Valuation and Growth Sustainability Concerns